Welcome back to Endpoints Weekly! We’ve got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author Max Gelman. If you haven’t ...
Welcome back to Endpoints Weekly! We’ve got a team of reporters on the ground in Chicago this weekend for ASCO, including my fellow Weekly co-author …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
An ASCO preview: What to watch for at cancer research's big meeting
Weekly Rundown—Moffitt Cancer Center expands Reimagine Care's virtual oncology model; Tanner Health deploys AI workforce solution
BioNTech and Pfizer tout bispecifics data, and Pazdur sees silver lining at FDA
At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancer
Ahead of ASCO, all eyes on pancreatic cancer
Five biotech news updates to stay on top of today
What do early data from Utah's Doctronic AI pilot show?
Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer
Real-World Evidence in the AI Era: What You Can Unlock Depends on What You Build On
Pharmalittle: We're reading about Replimune drug getting third try at FDA approval, a Pfizer deal in China, and more
Here's what to watch for at ASCO, cancer research's big meeting, in Chicago.
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their…
In this week’s edition of InnovationRx, we look at a high-tech chair that could revolutionize cancer radiation therapy, AI…
Welcome back to Endpoints Weekly. The biggest news this week was Marty Makary’s resignation from his role as FDA Commissioner.…
Welcome back to another edition of Endpoints Weekly! My usual co-author Nicole DeFeudis was out this week on a much-deserved…
Stay up to date on the latest in health tech, digital health and health AI news with this weekly brief. This is news from the…
